Passage Bio, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Unaudited results cover the three months ended March 31, 2024. Passage Bio is a clinical-stage genetic medicines company with no approved products or product sales. Its lead clinical candidate, PBFT02, is being studied for frontotemporal dementia caused by progranulin deficiency (FTD-GRN). The company also has one preclinical Huntington’s disease program.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 or comparison |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $11.5 million | $16.8 million |
| General and administrative expense | $6.5 million | $19.0 million |
| Operating loss | $18.1 million | $35.9 million |
| Other income, net | $1.3 million | $1.5 million |
| Net loss | $16.7 million | $34.3 million |
| Net loss per share, basic and diluted | $0.30 | $0.63 |
| Operating cash used | $18.9 million | $22.4 million |
| Cash, cash equivalents and marketable securities | $104.5 million at March 31, 2024 | $114.3 million at December 31, 2023 |
Cash and cash equivalents were $36.8 million and marketable securities were $67.8 million at quarter-end. Total assets were $140.5 million; total liabilities were $35.6 million, including $26.5 million of operating lease liabilities. The filing reports no credit facility or committed external capital source. Accumulated deficit was $611.2 million. No meaningful operating margin is applicable because the company had no product revenue.
Material changes versus the prior comparable period
- Net loss narrowed by $17.6 million year over year. R&D expense fell $5.3 million, reflecting lower activity in GM1 and Krabbe programs, reduced headcount-related costs, lower Penn expenses, and lower external manufacturing costs.
- G&A expense fell $12.5 million, primarily because Q1 2023 included $11.3 million of Catalent-related expenses: a $6.0 million payment obligation and a $5.3 million write-off of a prepaid asset.
- Operating cash use improved by $3.5 million year over year. Investing cash inflow mainly reflected $39.1 million of marketable-security sales and maturities, offset by $13.8 million of purchases.
- The company issued 6.0 million shares under its at-the-market (ATM) facility, generating $8.7 million net proceeds after $0.3 million of offering costs. Shares outstanding increased from 54.9 million at December 31, 2023 to 61.6 million at March 31, 2024.
Outlook, management commentary, risks and contingencies
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into Q4 2025. The filing cautions that this estimate depends on assumptions and may change. The financial statement note also says resources are expected to cover at least the next 12 months from issuance.
- Management expects R&D and G&A expenses to remain consistent in the near future, with spending potentially increasing if programs advance to later-stage trials. The company expects continuing losses and will need additional capital; financing may dilute shareholders or be unavailable on acceptable terms.
- PBFT02: the company reported initial safety and biomarker data from three Cohort 1 patients. Dose 1 was generally well tolerated in participants receiving enhanced immunosuppression; CSF progranulin increased, while plasma levels were not meaningfully altered. Cohort 1 dosing (n=5) was completed. Cohort 2 dosing (n=3–5) was expected to begin in Q2 2024, subject to IDMC safety review. Management expected six-month Cohort 1 data in H2 2024 and 12-month Cohort 1 plus initial Cohort 2 data in H1 2025.
- Management expected regulatory feedback on a potential PBFT02 clinical pathway for FTD-C9orf72 and ALS in H2 2024. It plans preclinical work in Alzheimer’s disease. These are forward-looking expectations, not guaranteed outcomes.
- To reduce costs, the company stopped further clinical development of PBGM01 (GM1), PBKR03 (Krabbe) and PBML04 (MLD) and is pursuing out-licensing; it also paused the PBAL05 and temporal-lobe epilepsy research programs. No active exploratory Penn research programs were reported.
- The company remains obligated on its Philadelphia and New Jersey leases despite office subleases. Future undiscounted lease payments were $44.1 million, before $17.6 million of imputed interest. It reported a $5.0 million annual Penn discovery-research funding commitment through June 2026. Catalent minimum annual purchase and clean-room commitments were eliminated; the remaining $2.0 million payment was paid in May 2024.
- A former employee seeks a mid-single-digit-million-dollar amount in a contract and wage-law dispute. The case was expected to go to trial in 2024; the company disputes the claim and had not recorded a loss contingency reserve.
- Key risks include reliance on PBFT02 as the sole clinical-stage candidate, uncertain clinical and regulatory outcomes, gene-therapy safety and manufacturing risks, dependence on Penn and third-party manufacturers, financing needs, and the possibility that early biomarker findings may not predict later clinical benefit. Disclosure controls were assessed as effective at a reasonable assurance level; no material internal-control changes were reported.
Important facts for investors to verify
- Updated cash runway, quarterly cash burn, and the assumptions behind management’s Q4 2025 runway estimate.
- PBFT02 Cohort 1 safety and durability data, IDMC review, Cohort 2 enrollment and dosing, and timing of subsequent readouts.
- Whether regulatory feedback supports expansion into FTD-C9orf72 or ALS and what additional studies or resources those indications require.
- Progress and potential economics of out-licensing GM1, Krabbe and MLD programs, and any further pipeline prioritization.
- Future ATM or other financing activity, resulting dilution, and the outcome of the former-employee litigation.